study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide is a formulation for sustained administration of a low dose of budesonide using a vehicle similar to lung surfactant.
Konduri et al., 5/5/2021, preprint, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.